Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $593.0K | $-45.85M | $-0.69 |
| 2024 | $683.0K | $-45.43M | $-0.95 |
| 2023 | $488.0K | $-41.44M | $-0.93 |
| 2022 | $386.0K | $-38.70M | $-0.89 |
| 2021 | $359.0K | $-28.29M | $-0.73 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise -5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.14 vs $-0.12miss
- Thu, May 14$-0.18 vs $-0.13miss
- Tue, Feb 24$-0.11 vs $-0.18beat
- Thu, Nov 6$-0.17 vs $-0.20beat
- Tue, Jul 29$-0.21 vs $-0.19miss
- Thu, May 8$-0.20 vs $-0.19miss
Estimates and results for CRDF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CRDFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Neutral
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC
View source ↗